Skip to main content

Table 1 Demographic and clinical characteristics of the patients

From: Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease

Subject

Age (years)/sex

Symptom duration (years)

MDS-UPDRS-III

H&Y

LEDD (mg)a

Days between PET 1–2

Avg. steps/dayb

Avg. magnitude counts/dayb

PET1

PET2

PET1

PET2

PET1

PET2

1

67/F

8

16

16

1

425

7

5133

6925

296,027

390,733

2

68/M

7

10

9

1

500

7

11,904

7254

584,009

369,687

3

56/F

14

16

21

1

680

7

6496

4429

345,169

335,207

4

71/M

5

18

28

1

560

7

4361

4770

261,553

275,948

5

69/M

8

30

30

2

675

20

5428

6854

340,436

403,469

6

54/M

3

10

7

2

650

28

7232

6930

422,193

368,935

7

74/M

8

25

20

2

400

7

3976

6152

267,269

350,235

8

47/M

2.5

3

6

1

320

17

7084

7166

501,065

524,408

9

67/F

5

40

36

2.5

300

7

3091

5971

248,016

323,042

10

61/M

2.5

16

16

2

150

14

12,020

11,801

676,188

857,889

Mean ± SD

63.4 ± 8.6

6.3 ± 3.5

18.2 ± 10.8

18.7 ± 10.2

 

465 ± 180

Median

   

1.5

 

7

5962

6889

342,803

369,311

  1. MDS-UPDRS-III Movement Disorder Society Unified Parkinson’s Disease Rating Scale, part 3, motor function (range 0–72). Assessed before PET1 and PET2, respectively; H&Y Hoehn and Yahr stage (range 1–5); LEDD levodopa equivalent daily dose
  2. aNo changes in LEDD have occurred between PET assessments
  3. bAssessed with the activity monitor (Actigraph GT3X+)